Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-16 pm EDT 		After market 04:37:38 pm
48.26 USD -0.52% Intraday chart for Bristol-Myers Squibb Company 48.35 +0.19%
Apr. 15 Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept MT
Apr. 15 Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept
MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating
MT
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
PR
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58
MT
TORL BioTherapeutics LLC announced that it has received $158 million in funding from a group of investors
CI
Bristol Myers: cancer treatment results
CF
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating
MT
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
BU
Bristol Myers Squibb Announces KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer
CI
Global markets live: Boeing, Shell, AstraZeneca, Tesla, Meta...
Our Logo
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy
AQ
Bristol Myers: new data on schizophrenia
CF
 Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
BU
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
BU
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
RE
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication
MT
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
DJ
Bristol Myers: FDA approves Abecma in multiple myeloma
CF
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company